Advertisement
Screener

LISATA THERAPEUTICS, INC. (LSTA) Net Income (Loss) Attributable to Noncontrolling Interest

1.6 / 5 stars · 15/46 Roast Me

LISATA THERAPEUTICS, INC. Net Income (Loss) Attributable to Noncontrolling Interest

LISATA THERAPEUTICS, INC. (LSTA) reported Net Income (Loss) Attributable to Noncontrolling Interest of $141.26 thousand for the 3-month period ending 2012-03-31, per its 10-Q filed 2012-05-11.

Discontinued › Income Statement › Net Income

us-gaap:NetIncomeLossAttributableToNoncontrollingInterest · last filed 2012-05-11

  • LISATA THERAPEUTICS, INC. net income (loss) attributable to noncontrolling interest for the quarter ending 2012-03-31 was $141.26K, a 70.15% decline year-over-year.
  • LISATA THERAPEUTICS, INC. net income (loss) attributable to noncontrolling interest for the quarter ending 2011-12-31 was -$10.01M.
  • LISATA THERAPEUTICS, INC. net income (loss) attributable to noncontrolling interest for the quarter ending 2011-09-30 was $17.97K, a 98.43% decline year-over-year.
  • LISATA THERAPEUTICS, INC. net income (loss) attributable to noncontrolling interest for the quarter ending 2011-06-30 was $67.88K, a 95.79% decline year-over-year.
  • LISATA THERAPEUTICS, INC. net income (loss) attributable to noncontrolling interest for fiscal 2011 was -$9.45M, a 341.73% decline from fiscal 2010.
  • LISATA THERAPEUTICS, INC. net income (loss) attributable to noncontrolling interest for fiscal 2010 was $3.91M.
Period endNet Income (Loss) Attributable to Noncontrolling Interest 3 monthNet Income (Loss) Attributable to Noncontrolling Interest 6 monthNet Income (Loss) Attributable to Noncontrolling Interest 9 monthNet Income (Loss) Attributable to Noncontrolling Interest 12 month
2012-03-31$141.26K
10-Q · filed 2012-05-11
-$9.87M
derived: sum of 2 quarters · filed 2012-05-11
-$9.85M
derived: sum of 3 quarters · filed 2012-05-11
-$9.78M
derived: sum of 4 quarters · filed 2012-05-11
2011-12-31-$10.01M
derived: 10-K 12 month − 10-Q 9 month · filed 2012-03-20
-$9.99M
derived: sum of 2 quarters · filed 2012-03-20
-$9.92M
derived: sum of 3 quarters · filed 2012-03-20
-$9.45M
10-K · filed 2012-03-20
2011-09-30$17.97K
10-Q · filed 2011-11-10
$85.85K
derived: sum of 2 quarters · filed 2011-11-10
$559.08K
10-Q · filed 2011-11-10
$382.03K
derived: sum of 4 quarters · filed 2012-05-11
2011-06-30$67.88K
10-Q · filed 2011-08-12
$541.11K
10-Q · filed 2011-08-12
$364.06K
derived: sum of 3 quarters · filed 2012-05-11
$1.51M
derived: sum of 4 quarters · filed 2012-05-11
2011-03-31$473.23K
10-Q · filed 2012-05-11
$296.18K
derived: sum of 2 quarters · filed 2012-05-11
$1.44M
derived: sum of 3 quarters · filed 2012-05-11
$3.05M
derived: sum of 4 quarters · filed 2012-05-11
2010-12-31-$177.05K
derived: 10-K 12 month − 10-Q 9 month · filed 2012-03-20
$968.53K
derived: sum of 2 quarters · filed 2012-03-20
$2.58M
derived: sum of 3 quarters · filed 2012-03-20
$3.91M
10-K · filed 2012-03-20
2010-09-30$1.15M
10-Q · filed 2011-11-10
$2.76M
derived: sum of 2 quarters · filed 2011-11-10
$4.09M
10-Q · filed 2011-11-10
2010-06-30$1.61M
10-Q · filed 2011-08-12
$2.94M
10-Q · filed 2011-08-12

Similar stocks

Stock NameCountryMarket CapPE Ratio
Vistagen Therapeutics, Inc. (VTGN)United States$0.013B-0.14
MUSTANG BIO, INC. (MBIO)United States$0.013B
BullFrog AI Holdings, Inc. (BFRG)United States$0.014B
AEON Biopharma, Inc. (AEON)United States$0.013B-0.36
Vyome Holdings, Inc (HIND)United States$0.014B-1.38
Tvardi Therapeutics, Inc. (TVRD)United States$0.014B
Tempest Therapeutics, Inc. (TPST)United States$0.013B
Aspire Biopharma Holdings, Inc. (ASBP)United States$0.012B-0.60
ACTUATE THERAPEUTICS, INC. (ACTU)United States$0.015B
BIOVIE INC. (BIVI)United States$0.012B